Evidence map›Paper›PMID 35976545›Full record

ArticleJournal of neuro-oncology2022

EGFR mutant status and tyrosine-kinase inhibitors affect the GKRS outcomes for NSCLC brain metastases.

Hung-Ruei Liao, Chi-Lu Chiang, Chia-I Shen, Ching-Jen Chen, Huai-Che Yang, Hsiu-Mei Wu, Yung-Hung Luo, Yong-Sin Hu, Chung-Jung Lin, Wen-Yuh Chung and 4 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Hung-Ruei LiaoDepartment of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan.
Chi-Lu ChiangSchool of Medicine, National Yang-Ming University, Taipei, Taiwan.
Chia-I ShenSchool of Medicine, National Yang-Ming University, Taipei, Taiwan.
Ching-Jen ChenDepartment of Neurosurgery, the University of Texas Health Science Center, Houston, TX, USA.
Huai-Che YangDepartment of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan.
Hsiu-Mei WuDepartment of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan.
Yung-Hung LuoSchool of Medicine, National Yang-Ming University, Taipei, Taiwan.
Yong-Sin HuDepartment of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan.
Chung-Jung LinDepartment of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan.
Wen-Yuh ChungDepartment of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan.
Cheng-Ying ShiauSchool of Medicine, National Yang-Ming University, Taipei, Taiwan.
Wan-Yuo GuoDepartment of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan.
David Hung-Chi PanDepartment of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan.
Cheng-Chia LeeDepartment of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan. yfnaughty@gmail.com.
National Yang Ming Chiao Tung University · TWTaipei Veterans General Hospital · TWKaohsiung Veterans General Hospital · TWNational Yang Ming Chiao Tung University · TWTaipei Medical University-Shuang Ho Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTyrosine kinase inhibitors (TKIs) is the first-line treatment for EGFR-positive non-small cell lung cancer (NSCLC); however, its applicability to patients with wild-type NSCLC remains an issue of contention. This study compared the effects of gamma knife radiosurgery (GKRS) alone versus combining GKRS and TKIs in treating two genetic forms of NSCLC.

methodsThis retrospective study examined 479 NSCLC patients with 1982 brain metastases who underwent GKRS and for whom imaging follow-up data or death records were available. All our patients were consecutive. All gene mutations were confirmed by lung biopsy. The three main endpoints in this study were overall survival (OS), local intracranial tumor control (LC), and distal intracranial tumor control (DC).

resultsThere were 296 NSCLC patients with EGFR positive: TKI treatment (n = 262) and without TKI treatment (n = 34). GKRS + TKIs was more effective than GKRS alone in terms of OS (HR 0.53, p = 0.085) and DC (HR 0.51, p < 0.001). There were 150 NSCLC patients with wild-type EGFR: TKI treatment (n = 50) and without TKI treatment (n = 100). GKRS + TKIs was less effective than GKRS alone in terms of OS (HR 1.82, p = 0.049) and DC (HR: 1.40, p = 0.011). We observed no difference in terms of LC in both genetic groups.

conclusionsCombining GKRS with TKIs proved effective in EGFR positive NSCLC patients; however, we do not observe the similar results when combining GKRS with TKIs for patients with wild-type NSCLC.

Indexed as

Brain NeoplasmsCarcinoma, Non-Small-Cell LungErbB ReceptorsLung NeoplasmsProtein Kinase InhibitorsRadiosurgeryHumansMutationRetrospective StudiesEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsBrain metastasisEGFRGamma knifeMutationsNon-small cell lung cancerRadiosurgeryStereotactic surgerySurvivalTumor controlTyrosine-kinase inhibitorWild type

Identifiers

PMID35976545
OpenAlexW4293064527

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.